MII IG Kerndatensatz-Modul Molekulares Tumorboard
2027.0.0-ballot.1 - Germany

This page is part of the MII Implementation Guide Molecular Tumor Board (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

Example MedicationStatement: 24.06.2023 Z1 Mirvetuximab soravtansine 6mg/kg KG, Wdh d22

English

basedOn: MedicationRequest: extension = 1,Predictive value of the biomarker or clinical effectiveness of the corresponding drug in a molecularly stratified cohort was demonstrated in a prospective study or a meta-analysis in the same tumor type.,http://doi.org#10.1200/JCO.2022.40.16_suppl.5512,http://www.ncbi.nlm.nih.gov/pubmed#38055253; status = completed; intent = proposal; medication[x] = MIRVETUXIMAB SORAVTANSINE; authoredOn = 2023-03-28

partOf: Procedure Zytostatische Chemotherapie, Immuntherapie und antiretrovirale Therapie

status: Completed

medication: MIRVETUXIMAB SORAVTANSINE

subject: Kim Musterperson (no stated gender), DoB: 1956-03-14

effective: 2023-06-24 --> 2023-06-24

note:

24.06.2023 Z1 Mirvetuximab soravtansine 6mg/kg KG, Wdh d22

dosage

timing: Events: 2023-06-24

DoseAndRates

-TypeDose[x]
*volle-Dosis6 mg/kg KG (Details: UCUM codemg/kg{KG} = 'mg/kg{KG}')